ArticlePathology research international2010
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.
Article in Pathology research international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 55 citations in OpenAlex.
- HER2/neu testing in primary colorectal carcinoma.British journal of cancer · 2014Trial
- HER2 testing: evolution and update for a companion diagnostic assay.Nature reviews. Clinical oncology · 2025Review
- Association of HER2 amplification or overexpression with overall survival in advanced upper gastrointestinal adenocarcinomas.BJC reports · 2025Article
- Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer.Health science reports · 2024Article
- Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.BMC cancer · 2022Article
- Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles.Drug delivery · 2020Article
- Expression of HER-2/neu in Oral Squamous Cell Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Evaluation of the expression of the oncogen C-ERBB-2/HER2 in advanced gastric cancer cases from Costa Rica.Ecancermedicalscience · 2019Article
- Biomarkers of gastric cancer: Current topics and future perspective.World journal of gastroenterology · 2018Review
- Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer.OncoTargets and therapy · 2018Article
- Targeted therapy in gastric cancer.European surgery : ACA : Acta chirurgica Austriaca · 2016Article
- C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome.Journal of Cancer · 2016Article
- Integrated Proteomic and Genomic Analysis of Gastric Cancer Patient Tissues.Journal of proteome research · 2015Article
- HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India.The Indian journal of surgery · 2015Article
- Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections.BMC gastroenterology · 2015Article
- HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas.Journal of clinical and diagnostic research : JCDR · 2015Article
- Recent advances in the HER2 targeted therapy of gastric cancer.World journal of clinical cases · 2015Review
- HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters.Ulusal cerrahi dergisi · 2015Article
- Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry.Experimental and therapeutic medicine · 2014Article
- Molecular targeting to treat gastric cancer.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite ongoing advances in the treatment of gastroesophageal cancer, prognosis remains poor. The best promise to improve this poor survival is provided by new targeted agents. Of these, human epidermal growth factor receptor 2 (HER2) is currently in the spotlight. In this review, we provide an overview of recent developments in HER2 testing and results of clinical trials targeting HER2 in gastroesophageal adenocarcinoma. Based on the encouraging ToGA trial findings it is now expected that routine HER2 testing will be included in the diagnostic work-up of patients with advanced gastric cancer. With regard to this testing, overexpression of the HER2 protein seems to possess the best predictive properties. However, HER2 immunohistochemistry (IHC) is subject to assay and interobserver variability, so standardization and internal and external proficiency testing is an absolute prerequisite, especially as the IHC scoring system in gastric cancer is different from that of breast cancer. Further study is needed to investigate the clinical meaning of the significant heterogeneity observed in both gene amplification and protein overexpression in gastroesophageal cancer. Highly effective therapies for gastroesophageal cancer can only be accomplished by a multi-targeted approach, considering crosstalk between pathways and continuing to optimize chemotherapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.